Enzymatic studies on possible improvement of cytosine arabinoside treatment.
Initial phosphorylation and deamination of cytosine arabinoside (Ara-C) and the natural metabolite deoxycytidine (CdR) were estimated in cell free extracts of leucocytes from patients with CML and controls. Phosphorylation of CdR had been increased while deamination of CdR in extracts of CML cells from peripheral blood had been decreased compared with normal leucocytes. Comparing the ratios between Ara-C and CdR phosphorylation it was revealed that these were twice as high in CML cells as in normal leucocytes, whereas no difference was found when comparing ratios between Ara-C and CdR deamination. From these discoveries it is proposed that Ara-C can be combined with CdR with advantage, because apparently CdR protects the normal cells more than the malignant ones.
D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000097:blood / Q000627:therapeutic use*; D003564:Cytidine Deaminase / Q000097:blood; D003641:Deamination; D003842:Deoxycytidine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000201:enzymology; D007962:Leukocytes / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation
D003561:Cytarabine; D003842:Deoxycytidine Kinase; D003564:Cytidine Deaminase